Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Apple Turns 50: From Garage Startup to AI Crossroads 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
BERKELEY, Calif., Dec. 27, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2017, at 10:00 am Pacific Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
